for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Incyte Corporation

INCY.O

Latest Trade

80.74USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

62.48

 - 

110.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
80.74
Open
--
Volume
--
3M AVG Volume
24.53
Today's High
--
Today's Low
--
52 Week High
110.36
52 Week Low
62.48
Shares Out (MIL)
218.90
Market Cap (MIL)
17,799.92
Forward P/E
-130.05
Dividend (Yield %)
--

Next Event

Incyte Corp at Evercore ISI HealthCONx Conference

Latest Developments

More

Incyte Reports Qtrly Loss Per Share $0.07

Macrogenics Says Entered Into Commercial Supply Agreement With Incyte Corp

Eli Lilly Says Continuing Conversations With U.S. FDA Around Potential For EUA Of Baricitinib

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Industry

Biotechnology & Drugs

Contact Info

1801 Augustine Cut off

WILMINGTON, DE

19803-4404

United States

+1.302.4986700

https://www.incyte.com/

Executive Leadership

Herve Hoppenot

Chairman of the Board, President, Chief Executive Officer

Christiana Stamoulis

Chief Financial Officer, Executive Vice President

Dashyant Dhanak

Executive Vice President, Chief Scientific Officer

Maria E. Pasquale

Executive Vice President, General Counsel

Paula J. Swain

Executive Vice President - Human Resources

Key Stats

2.35 mean rating - 20 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.5K

2018

1.9K

2019

2.2K

2020(E)

2.5K
EPS (USD)

2017

-1.530

2018

1.040

2019

2.830

2020(E)

-0.630
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.25
Price To Book (MRQ)
7.45
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.95
LT Debt To Equity (MRQ)
1.37
Return on Investment (TTM)
-12.27
Return on Equity (TTM)
-10.26

Latest News

Latest News

BRIEF-Incyte And MorphoSys Announce The Validation Of The European Marketing Authorization Application For Tafasitamab

* INCYTE AND MORPHOSYS ANNOUNCE THE VALIDATION OF THE EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR TAFASITAMAB

BRIEF-Incyte Says Paul Friedman Notified He Will Serve Until 2021 Annual Meeting If Re-Elected As Board Member

* INCYTE - ON MAY 13 PAUL A. FRIEDMAN, M.D. NOTIFIED CO THAT SHOULD HE BE RE-ELECTED AS MEMBER OF BOARD HE WILL SERVE UNTIL 2021 ANNUAL MEETING

BRIEF-Incyte Reports Q1 Loss Per Share Of $3.33

* INCYTE REPORTS 2020 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES UPDATES ON KEY CLINICAL PROGRAMS

BRIEF-Incyte Announces Pivotal Reach2 Study Data Published In Nejm Highlight Superior Efficacy Of Ruxolitinib Versus Best Available Therapy In Patients With Acute Graft-Versus-Host Disease

* INCYTE ANNOUNCES PIVOTAL REACH2 STUDY DATA PUBLISHED IN NEJM HIGHLIGHT SUPERIOR EFFICACY OF RUXOLITINIB (JAKAFI®) VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE Source text for Eikon: Further company coverage:

BRIEF-FDA Approves First Targeted Treatment For Patients With Cholangiocarcinoma

* FDA APPROVES FIRST TARGETED TREATMENT FOR PATIENTS WITH CHOLANGIOCARCINOMA, A CANCER OF BILE DUCTS

BRIEF-Incyte Announces Initiation Of Phase 3 Ruxcovid Study Evaluating Ruxolitinib (Jakafi®) As A Treatment For Patients With Covid-19 Associated Cytokine Storm

* INCYTE ANNOUNCES INITIATION OF PHASE 3 RUXCOVID STUDY EVALUATING RUXOLITINIB (JAKAFI®) AS A TREATMENT FOR PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM

BRIEF-Incyte Says Phase 3 Data From True-Ad Program Of Ruxolitinib Cream Support Planned Submission Of NDA To US FDA In 2020

* FIRST PRESENTATION OF PHASE 3 DATA FROM TRUE-AD PROGRAM OF RUXOLITINIB CREAM AT REVOLUTIONIZING ATOPIC DERMATITIS VIRTUAL SYMPOSIUM

RPT-Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19

Novartis and Incyte plan to test their drug Jakavi in patients with coronavirus-caused COVID-19, joining other firms including Roche and Sanofi hoping to repurpose older medicines to help critically ill patients.

Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19

Novartis and Incyte plan to test their drug Jakavi in patients with coronavirus-caused COVID-19, joining other firms including Roche and Sanofi hoping to repurpose older medicines to help critically ill patients.

BRIEF-Incyte Announces Plans To Initiate A Phase 3 Clinical Trial Of Ruxolitinib (Jakafi®) As A Treatment For Patients With Covid-19 Associated Cytokine Storm

* INCYTE ANNOUNCES PLANS TO INITIATE A PHASE 3 CLINICAL TRIAL OF RUXOLITINIB (JAKAFI®) AS A TREATMENT FOR PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM

BRIEF-Incyte Names New Member To Its Board Of Directors

* INCYTE NAMES NEW MEMBER TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Morphosys Resolves Capital Increase To Implement Purchase Of ADSs By Incyte

* DGAP-NEWS: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE PURCHASE OF 3,629,764 AMERICAN DEPOSITARY SHARES BY INCYTE CORPORATION

BRIEF-Morphosys, Incyte Announce Antitrust Clearance Of Global Collaboration And License Agreement For Tafasitamab

* DGAP-NEWS: MORPHOSYS AND INCYTE ANNOUNCE ANTITRUST CLEARANCE OF GLOBAL COLLABORATION AND LICENSE AGREEMENT FOR TAFASITAMAB

BRIEF-Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream In Patients With Atopic Dermatitis

* INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 TRUE-AD PROGRAM EVALUATING RUXOLITINIB CREAM IN PATIENTS WITH ATOPIC DERMATITIS

BRIEF-Incyte Corp - QTRLY Non-GAAP Diluted EPS $0.65

* INCYTE REPORTS 2019 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS AND PROVIDES 2020 FINANCIAL GUIDANCE AND UPDATES ON KEY CLINICAL PROGRAMS

BRIEF-Lilly And Incyte Announce Positive Top-Line Results From The North American Phase 3 Study Of Oral Selective JAK Inhibitor Baricitinib In Patients With Moderate- To Severe Atopic Dermatitis

* LILLY AND INCYTE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM THE NORTH AMERICAN PHASE 3 STUDY (BREEZE-AD5) OF ORAL SELECTIVE JAK INHIBITOR BARICITINIB IN PATIENTS WITH MODERATE- TO SEVERE ATOPIC DERMATITIS

UPDATE 1-Incyte's skin disease drug meets main goal in late-stage study

Drugmaker Incyte said on Tuesday its cream to treat a type of skin disease met its main goal of improving the skin condition of patients with atopic dermatitis in a late-stage study.

Incyte's skin disease drug meets main goal in late-stage study

Drugmaker Incyte said on Tuesday its cream to treat a type of skin disease met its main goal of improving skin clarity in patients with atopic dermatitis in a late-stage study.

Incyte unlawfully marketed cancer drug Jakafi says whistleblower lawsuit

Biopharmaceutical company Incyte Corp has engaged in a series of unlawful marketing and kickback schemes aimed at promoting the sale of its blockbuster bone marrow cancer drug Jakafi, a newly unsealed whistleblower lawsuit alleges.

BRIEF-FDA Approves Jakafi For The Treatment Of Patients With Acute Graft-Versus-Host Disease

* FDA APPROVES JAKAFI® (RUXOLITINIB) FOR THE TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up